Therapeutic approaches to vascular Ehlers–Danlos syndrome
Potential therapeutic approaches to vascular Ehlers–Danlos syndrome. Celiprolol may reduce total peripheral resistance by dilating skeletal muscle resistance vessels through β2-adrenergic receptors and might decrease arterial wall shear stress by lowering heart rate through β1-adrenergic receptor antagonism. This drug could also reduce vascular oxidative stress at the arterial wall level by stimulating nitric oxide production. Lastly, it might increase arterial stiffness by enhancing TGFβ-mediated pro-fibrotic mechanisms and promoting collagen synthesis via β1 antagonism and β2 stimulation, respectively. By acting on angiotensin receptors, sartans could provide vascular protection either by inducing vasodilation or by limiting the adverse effects of angiotensin II on vascular remodeling. Targeting matrix metalloproteinases (MMPs) via doxycycline might counteract collagen degradation, thereby increasing its content in the arterial wall and enhancing vessel stiffness. Inhibition of phospholipase C/inositol 1,4,5-triphosphate/protein kinase C/extracellular signal-regulated kinase (PLC/IP3/PKC/ERK) has been shown to prevent spontaneous fatal aortic rupture in a mouse model. Antiandrogen medications may also contribute by interfering with this signaling pathway. Future research should identify drugs capable of improving mechanisms of autophagy, endoplasmic reticulum (ER) homeostasis, and stress response, which are likely to contribute substantially in the natural history of vEDS. Red lines: inhibition; green lines: stimulation; AR: androgen receptor; AT1R: angiotensin 1 receptor; β2AR: β2-adrenergic receptor; DHT: dihydrotestosterone; ECM: extracellular matrix; ER: endoplasmic reticulum; MMP: matrix metalloproteinase
Current Evidence and Future Perspectives in the Medical Management of Vascular Ehlers–Danlos Syndrome: Focus on Vascular Prevention (2024)
Giacomo Buso, et al. J Clin Med. 2024 Jul;13(14). Figure: F1.